Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06451614 · ClinicalTrials.gov registry record · NA
SpaceIT Hydrogel System for Perirectal Spacing
A NA study of Prostate Cancer, sponsored by Boston Scientific Corporation.
- Active
- Registry status
- NA
- Development phase
- 230
- Enrollment target
- 20
- Study locations
NCT06451614: Active NA study of Prostate Cancer, sponsored by Boston Scientific Corporation.
NCT06451614 is a NA study of Prostate Cancer that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 230 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06451614, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by Boston Scientific Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 230 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and effectiveness of the SpaceIT™ Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.
Primary Outcome
Acute Grade 3 or greater adverse events, inclusive of all adverse events listed on the existing SpaceOAR product labels, that arise within 90 days of index procedure.
Conditions Studied
Interventions
- DEVICE SpaceIT Hydrogel System
- DEVICE Commercially available Boston Scientific Spacer
Study Locations (20)
New York
- Integrated Medical Professionals - New York
- Perlmutter Cancer Center - NYU Langone - New York
- Memorial Sloan Kettering - New York
- Northwell Health - New York
California
- City of Hope - Duarte
- Orange County Urology Associates - Laguna Hills
- Ronald Reagan UCLA Medical Center - Los Angeles
Illinois
- Associated Urological Specialists - Chicago Ridge
- UroPartners - Glenview
- Springfield Clinic, LLC - Springfield
Florida
- Baptist Hospital of Miami - Miami
- Orlando Health Cancer Institute - Orlando
Ohio
- University Hospitals of Cleveland-Hospital - Cleveland
- Mercy Cancer Center Bon Secours Mercy Healt - Elyria
Pennsylvania
- MidLantic Urology - Bala-Cynwyd
- Perelman Center for Advanced Medicine - Philadelphia
Georgia
- Emory University Hospital - Atlanta
Kansas
- University of Kansas Hospital - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
What the registry record for NCT06451614 still lists
NCT06451614 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which SpaceIT Hydrogel System is the first listed.
NCT06451614 names 20 study sites across 10 states, led by New York, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06451614 about?
NCT06451614 is a clinical study titled "SpaceIT Hydrogel System for Perirectal Spacing". To evaluate the safety and effectiveness of the SpaceIT™ Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.
What is the current status of trial NCT06451614?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 230 participants. The study started on 2024-10-30. Estimated completion is 2028-03-31.
What conditions does trial NCT06451614 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06451614?
The interventions under investigation include: SpaceIT Hydrogel System (DEVICE), Commercially available Boston Scientific Spacer (DEVICE).
Who is sponsoring clinical trial NCT06451614?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06451614 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06451614's enrollment target sits among peer trials
230 198th of 735 higher than 537 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI